STOCK TITAN

Codexis, Inc. - CDXS STOCK NEWS

Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.

Codexis, Inc. (Symbol: CDXS) is a pioneering leader in protein engineering, pushing the boundaries of biotechnology through its innovative approaches. Established in 2002, Codexis specializes in the rapid development and production of highly optimized proteins using its proprietary CodeEvolver® technology platform. This platform leverages the power of artificial intelligence and advanced high-throughput screening systems to efficiently introduce function-driven mutations, creating proteins meticulously tailored to meet specific performance requirements.

Codexis offers a broad spectrum of enzyme optimization services and biocatalyst products. These include biocatalysts and enzymes, which play crucial roles in various industries, including pharmaceuticals, food, and biofuels. The company's enzyme solutions are designed to improve the efficiency, cost-effectiveness, and environmental sustainability of production processes.

A significant portion of Codexis’ revenue is derived from product sales, while licensing its technology platform to pharmaceutical companies also contributes to its financial health. These partnerships enable pharmaceutical giants to harness Codexis’ technology in-house, facilitating the engineering of custom enzymes for their specific needs.

Codexis has a global revenue footprint, with contributions from the United States, Ireland, Switzerland, China, and other international markets. The company's innovative efforts have led to several strategic partnerships and collaborations, further cementing its position in the biotechnology sector.

Recent achievements include a strategic collaboration geared towards enhancing RNA therapeutic development, aimed at providing GMP-grade Codexis enzymes. Another notable development is the collaboration with TnX transposase, focusing on enhancing genomic applications.

Codexis continues to advance in the field of biotherapeutics, retaining economic interest while minimizing development and commercialization costs. The company remains committed to optimizing yield, purity, and quality in its offerings, ensuring that customers receive superior siRNA materials for preclinical testing.

For more information, Codexis frequently participates in industry conferences, presenting breakthrough research and advancements. Stay updated with the latest developments and announcements by following Codexis on various platforms.

Rhea-AI Summary

Codexis (Nasdaq:CDXS) announced key presentations at the 14th International Congress of Inborn Errors of Metabolism 2021, highlighting potential treatments for homocystinuria and maple syrup urine disease. The oral presentations will take place on November 21, 2021, featuring CDX-6512, a methionine-gamma-lyase enzyme therapy for homocystinuria, and a bacterial leucine decarboxylase therapy for maple syrup urine disease. Both will be presented by Dr. Kristen Skvorak, emphasizing innovative drug development efforts by Codexis to leverage synthetic biology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.76%
Tags
conferences
-
Rhea-AI Summary

Codexis has appointed Karen Frechou-Armijo as Senior Vice President of Human Resources and Asli Aras, Ph.D., as Vice President of Corporate Development. Frechou-Armijo brings extensive HR experience, previously growing employee numbers at Cepheid significantly. Dr. Aras, with a strong background in corporate development, will enhance Codexis’ inorganic growth strategy. Both executives report to John Nicols, President and CEO, who emphasized their roles in building a high-performance culture and advancing growth opportunities as Codexis prepares for a crucial year ahead.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.76%
Tags
management
-
Rhea-AI Summary

Codexis (Nasdaq: CDXS) announced participation in three upcoming virtual investment conferences on November 16-18, 2021, showcasing its leading enzyme engineering capabilities. The events include the 12th Annual Craig-Hallum Alpha Select Conference, the Stifel 2021 Virtual Healthcare Conference, and the Jefferies London Healthcare Conference with scheduled 1x1 meetings and fireside chats. Webcasts will be available on Codexis' Investor Relations webpage for 30 days post-event. Codexis' innovations in enzyme technology aim to enhance sustainable manufacturing and biotherapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.51%
Tags
conferences
Rhea-AI Summary

Codexis, Inc. (Nasdaq:CDXS) reported impressive financial results for Q3 2021, with total revenues reaching $36.8 million, a 100% increase from Q3 2020. Product revenues surged 242% to $28.7 million, driven by significant enzyme sales for Pfizer's COVID-19 antiviral candidate. The company achieved a record product gross margin of 76%. Codexis reiterated its total revenue guidance for FY 2021 at $98-103 million and raised product revenue guidance to $63-66 million. The company continues to expand its collaborations, including new agreements with Merck and Kalsec.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.9%
Tags
-
Rhea-AI Summary

Codexis (CDXS) announced a $10 million investment in Molecular Assemblies, Inc. (MAI) through the SynBio Innovation Accelerator, aimed at accelerating MAI's enzymatic DNA synthesis technology. This partnership, initiated in June 2020, seeks to make DNA synthesis more cost-effective.

Codexis is the second largest shareholder in MAI and has a board seat. The investment highlights Codexis' commitment to pioneering solutions in synthetic biology, necessary for enhancing DNA synthesis capabilities. The SynBio Innovation Accelerator supports early-stage companies with disruptive technologies in synthetic biology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.43%
Tags
none
-
Rhea-AI Summary

Codexis (NASDAQ: CDXS) has commenced a Phase 1 study for its novel biotherapeutic, CDX-7108, in collaboration with Nestlé Health Science. This enzyme aims to address exocrine pancreatic insufficiency (EPI) caused by conditions like pancreatitis and cystic fibrosis. The study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics through a randomized, double-blind trial with healthy subjects and EPI patients. This partnership leverages Codexis’ enzyme engineering platform for innovative therapies, signaling a significant advancement in treatment options for EPI patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.43%
Tags
Rhea-AI Summary

Codexis (Nasdaq: CDXS) will report its third quarter 2021 financial results on November 4, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET, where management will discuss the results and provide a business update. The call can be accessed domestically at 866-682-6100 and internationally at 862-298-0702, using conference ID #13724176. Codexis leverages its CodeEvolver® platform to develop high-performance enzymes for various applications, emphasizing sustainability and efficiency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
conferences earnings
-
Rhea-AI Summary

Codexis (CDXS) has entered a tri-party collaboration agreement with Almelo Private and RC2 Pharma Connect to license and use Codexis' proprietary enzyme for manufacturing sitagliptin, an active pharmaceutical ingredient for diabetes treatment. Almelo will develop and optimize the commercial manufacturing process, while RC2 will enhance supply chain efficiency for the future generic sitagliptin market. This partnership aims to reduce costs and improve production sustainability, positioning all parties for success in a competitive market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
none
-
Rhea-AI Summary

Codexis (Nasdaq: CDXS) announced an extension of its agreement with Merck to license and supply a proprietary enzyme used in the manufacturing of sitagliptin, the API in Merck’s JANUVIA® and JANUMET®. This partnership, which has lasted over a decade, will now extend through December 31, 2026, with a potential 5-year renewal. The enzyme enhances manufacturing efficiency, reducing costs and waste. Codexis and Merck previously won the EPA's Presidential Green Chemistry Challenge Award for their innovative manufacturing method.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
none
Rhea-AI Summary

Codexis (Nasdaq:CDXS), an enzyme engineering leader, announced its participation in two virtual investment conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will take place on September 13, 2021, featuring an on-demand corporate presentation. Following that, the Cantor Virtual Global Healthcare Conference is scheduled for September 28, 2021, with a fireside chat at 10:40 a.m. ET. Webcasts of both events will be available on the Company's Investor Relations website for 90 days post-event, highlighting Codexis' advancements in synthetic biology and enzyme technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences

FAQ

What is the current stock price of Codexis (CDXS)?

The current stock price of Codexis (CDXS) is $5.28 as of December 20, 2024.

What is the market cap of Codexis (CDXS)?

The market cap of Codexis (CDXS) is approximately 424.0M.

What does Codexis, Inc. specialize in?

Codexis specializes in the rapid development and production of optimized proteins using its proprietary CodeEvolver® technology platform.

How does Codexis generate revenue?

Codexis generates revenue primarily through product sales and by licensing its technology platform to pharmaceutical companies.

What industries benefit from Codexis’ products and services?

Industries such as pharmaceuticals, food, and biofuels benefit from Codexis’ enzyme optimization services and biocatalyst products.

What is the CodeEvolver® technology platform?

The CodeEvolver® technology platform is Codexis' proprietary method for rapidly developing highly optimized proteins through guided mutations and high-throughput screening.

Where does Codexis derive its revenue from geographically?

Codexis derives revenue from the United States, Ireland, Switzerland, China, and other international markets.

What recent collaborations has Codexis entered into?

Recent collaborations include a strategic partnership for RNA therapeutic development and a development collaboration with TnX transposase for genomic applications.

What is the significance of Codexis’ strategic collaborations?

These collaborations aim to enhance product efficiency, reduce costs, and expand the application of Codexis' enzyme technology in various fields.

What recent achievements has Codexis made in biotherapeutics?

Codexis has retained economic interest in biotherapeutic assets while minimizing development and commercialization costs, focusing on optimizing siRNA materials for preclinical testing.

How does Codexis ensure the quality of its products?

Codexis continues to enhance yield, purity, and quality, providing customers with high-standard siRNA materials comparable or superior to existing options.

How can I stay updated with Codexis’ latest news and developments?

Follow Codexis' presentations at industry conferences and keep an eye on their official announcements for the latest updates.

Codexis, Inc.

Nasdaq:CDXS

CDXS Rankings

CDXS Stock Data

423.98M
79.57M
2.23%
79.83%
2.07%
Biotechnology
Industrial Organic Chemicals
Link
United States of America
REDWOOD CITY